Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

rsuant to an opinion issued September 22, 2011 from the Delaware Court of Chancery, PharmAthene is entitled to 50% of the net profits over 10 years from all sales of SIGA Technologies' ST-246, a novel smallpox antiviral agent being developed by SIGA for the treatment and prevention of morbidity and mortality associated with exposure to the causative agent of smallpox, and related products, once SIGA receives the first $40 million in net profits from sales of ST-246.  For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manu
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
7. PharmAthene Completes $6.5 Million Registered Direct Offering
8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... date to $5 million. The orders are all odour control ... "We continue to see new orders coming in," said ... backlog has climbed to over $11 million." ... technology company that designs, manufactures and distributes a comprehensive line ...
(Date:9/23/2014)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... to announce that its wholly owned subsidiary, Portage ... to its team for further development of its ... cell permeable peptide platform technology derived from human ... eye. Ms. Holly Prentice ...
(Date:9/23/2014)... 2014   GenoSpace , a precision medicine software ... to enable the broad use of genomic data in ... been awarded Phase I of a Fast Track Small ... of Health (NIH) to enable enhanced data access and ... http://photos.prnewswire.com/prnh/20140922/147649 During the past decade, ...
(Date:9/23/2014)... Marktech Optoelectronics has introduced the MTE280xxx series, ... the 280 nm wavelength range. This series joins Marktech’s ... 280nm to 405nm. These new devices are suitable for ... curing. Mark Campito, Marktech’s CEO states that “what makes ... is that we offer it in one of the ...
Breaking Biology Technology:Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2Marktech Introduces its New Line of Deep UV Emitters 2
... , , , , , ... service for large insert vectors such as BACs, cosmids and fosmids. Agencourt , ... , rapid turnaround including: , ... strategies , Patented SPRI technology , ...
... ,Solutions Note ,, The time taken to ... for,researchers today. Whilst many manufacturers of,thermal cyclers focus ... article we highlight how Thermo's approach of focussing ... less than 1 hour. , Abstract ...
... , , , , RT-PCR amplification ... are specific for that mRNA sequence. The primer design should also , ... product derived from contaminating genomic DNA. There are two approaches , ... , , , , , ...
Cached Biology Technology:FULL LENGTH INSERT SEQUENCING 2Rapid PCR* Using Active Tube Temperature Control On Thermo's PCR Machines 2Rapid PCR* Using Active Tube Temperature Control On Thermo's PCR Machines 3
(Date:9/23/2014)... fall of an athlete,s moving body relies on an orchestrated ... angles and intersecting planes literally the geometry of ... But it,s more than just a footfall error at the ... the ACL or anterior cruciate ligament tear. In fact, size ... of the knee joint and volume of the ACL ...
(Date:9/23/2014)... Researchers have encountered variants or isoforms in microRNAs ... byproducts. A recent study, published in the journal ... isomiRs have abundances that depend on geographic subpopulations and ... given miRNA may not be the one typically listed ... microRNA isoforms are much more common than we had ...
(Date:9/23/2014)... Scientists often measure the effects of temperature on insects ... and abundance, but a Dartmouth study shows for the ... addition to temperature, ultimately limits how fast they grow. ... more about the overall environmental conditions that shape the ... lead author Lauren Culler , an Arctic postdoctoral ...
Breaking Biology News(10 mins):Does size matter? MRI imaging sheds light on athletes most at risk for severe knee injury 2Does size matter? MRI imaging sheds light on athletes most at risk for severe knee injury 3Slight alterations in microRNA sequences hold more information than previously thought 2Slight alterations in microRNA sequences hold more information than previously thought 3Insects' fear limits boost from climate change, Dartmouth study shows 2
... BETHESDA, MD, USA, DECEMBER 1, 2011 The collaboration ... a more extensive and advanced facility for archiving, sharing, ... American Society for Cell Biology (ASCB) and the National ... University of California, San Diego (UCSD), have joined forces ...
... COLUMBIA, Mo. When a muscle is damaged, ... to "wake up" and contribute to repairing the muscle. ... satellite cells could help with the repair, and are ... tissue. This knowledge could ultimately help doctors more effectively ...
... A Michigan State University researcher is using a ... a portable wastewater treatment system that could improve ... is being spearheaded by Wei Liao, an MSU ... will generate energy and produce drinking water, thus ...
Cached Biology News:2 top biological imaging centers offer powerful free online tool to researchers and public 2Adult stem cells use special pathways to repair damaged muscle, MU researchers find 2Wastewater system generates energy, produces drinking water 2